CompletedNCT00763971
Lisdexamfetamine or methylphenidate for ADHD in children and teens
About this title
Read the official source — NCT00763971Researchers compared Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
Medication studyAges 6–17Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Hoboken and 48 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: November 17, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 336
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00763971
- Official title
Show the full official title
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hoboken, Belgium · Ghent, Belgium · Leuven, Belgium
43 more locations
- Nice, France
- Bordeaux Cédex, France
- Montpellier, France
- Paris, France
- Mannheim, Germany
- Bamberg, Germany
- Würzburg, Germany
- Marburg, Germany
- Göttingen, Germany
- Mainz, Germany
- Berlin, Germany
- Freiburg im Breisgau, Germany
- Fulda, Germany
- Hagen, Germany
- Hamburg, Germany
- Budapest, Hungary
- Gyula, Hungary
- Pécs, Hungary
- Szeged, Hungary
- Cagliari, Italy
- Messina, Italy
- Naples, Italy
- Maastricht, Netherlands
- Nijmegen, Netherlands
- Bydgoszcz, Poland
- Torun, Poland
- Warsaw, Poland
- Gdansk, Poland
- Esplugues de Llobregat, Spain
- Torremolinos, Spain
- Pamplona, Spain
- San Cristóbal de La Laguna, Spain
- Badajoz, Spain
- Barcelona, Spain
- Madrid, Spain
- Mariestad, Sweden
- Gothenburg, Sweden
- Stockholm, Sweden
- Basildon, United Kingdom
- Southend-on-Sea, United Kingdom
- Kirkcaldy, United Kingdom
- Dundee, United Kingdom
- Sheffield, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride and Placebo.
Who was this study for?
Listed age limits: 6 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...